Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

IMW 2019 | AB322: timing the initiation of MM

Francesco Maura • 13 Sep 2019
IMW 2019
Multiple Myeloma

Francesco Maura, MD Memorial Sloan Kettering Cancer Center, New York, NY, explains how mutational processes can be used to predict myeloma outcomes at the International Myeloma Workshop (IMW) 2019, held in Boston, MA.

More from Francesco Maura

SMM & MGUS: clinical relevance, the PROMISE study & the role of genomics
Elizabeth O'Donnell et al. • 25 Mar 2024
3:43
Genomic profiling to predict prognosis for patients with HR-SMM
Francesco Maura • 8 Dec 2023
1:15
Using genomic alterations to predict relapse following immunotherapy in multiple myeloma
Francesco Maura • 8 Dec 2023
2:08
Novel genomic alterations driving tumor suppressor gene inactivation in multiple myeloma
Francesco Maura • 8 Dec 2023

Related Videos

0:59
Looking forward to COMy 2024: celebrating 10 years
Mohamad Mohty • 17 Apr 2024
0:57
Overcoming barriers to treating older patients with myeloma
Sergio Giralt • 16 Apr 2024
1:01
The potentially curative role of CAR-T therapy in myeloma
Sergio Giralt • 16 Apr 2024
1:45
Expanded approval of cilta-cel in myeloma: the value of bringing CAR-T cells into earlier lines
Monika Engelhardt • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals